SequelSEC

BioNexus Gene Lab Corp BGLC

Services-Medical Laboratories · CIK 0001737523 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$76.16K
Fiscal year ended 2026-06-30
Operating income
-$282.40K
Fiscal year ended 2026-06-30
Free cash flow
-$422.74K
Fiscal year ended 2026-06-30

BioNexus Gene Lab Corp (BGLC) reported revenue of $76.16K and net income of -$286.45K for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from BioNexus Gene Lab Corp’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Medical Laboratories.

Income

BioNexus Gene Lab Corp income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$76.16K$22.84K$483.76K$2.54M$2.26M$2.14M$2.52M$2.63M$1.97M$2.38M
Cost of revenue$63.17K$23.63K$487.74K$2.17M$1.89M$1.79M$2.21M$2.30M$1.69M$2.02M
Gross profit$12.98K-$790-$3.98K$377.68K$368.02K$343.49K$309.23K$326.54K$288.72K$365.03K
Operating income-$282.40K-$540.49K-$1.03M-$702.51K-$611.29K-$618.42K-$416.22K-$1.34M$259.17K-$79.03K
Net income-$286.45K-$543.58K-$1.04M-$708.99K-$616.17K-$623.33K-$348.32K-$1.35M$199.10K-$103.76K
Research & development$13.67K$14.49K$11.10K$14.88K$12.56K$12.14K$17.40K$10.44K$8.20K$11.48K
Weighted-average diluted sharesshares 2.42Mshares 2.42MUnavailableshares 1.80Mshares 1.80Mshares 1.80MUnavailableshares 1.80Mshares 1.77Mshares 17.67M
Pretax income-$286.45K-$543.58K-$1.04M-$708.99K-$616.17K-$623.33K-$422.03K-$1.34M$254.69K-$83.69K
Income tax expense$0$0$0$0$0$0-$80.70K$1.56K$55.58K-$20.07K
Diluted EPS$-0.12$-0.22Unavailable$-0.40$-0.34$-0.35Unavailable$-0.75$0.11$-0.01
Selling, general & administrative$334.55K$380.40K$216.74K$997.26K$1.13M$932.57K$660.80K$2.04M$695.32K$469.66K
General & administrative$298.53K$327.67K$181.10K$445.69K$516.79K$391.88K$165.93K$792.41K$558.83K$315.79K
Selling & marketing$36.02K$52.73K$35.64K$551.57K$608.43K$540.70K$494.86K$1.25M$136.49K$153.87K

Balance

BioNexus Gene Lab Corp balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$1.23MUnavailable$2.38MUnavailableUnavailableUnavailable$2.89MUnavailableUnavailableUnavailable
Total assets$8.73M$9.04M$9.25M$7.62M$9.42M$9.48M$10.43M$11.00M$11.14M$11.16M
Current assets$4.94M$5.20M$5.45M$5.63M$6.38M$6.54M$7.43M$7.04M$7.84M$7.91M
Total liabilities$947.98K$946.88K$637.86K$804.97K$1.90M$1.71M$2.11M$1.61M$1.59M$1.82M
Current liabilities$812.94K$796.47K$520.96K$678.02K$1.76M$1.56M$1.95M$1.41M$1.40M$1.72M
Total equity incl. NCI$7.78M$8.09M$8.61M$6.82M$7.52M$7.77M$8.32M$9.39M$9.55M$9.34M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$652.89K$667.15K$676.70K$1.01M$1.22M$1.18M$1.39M$1.39M$1.03M$1.08M
Accounts receivable$15.54K$79.86K$505.88K$1.52M$1.85M$1.44M$1.38M$1.43M$987.96K$839.56K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailable$1.18M$1.50M$1.03M$954.78K$1.43M

Cash flow

BioNexus Gene Lab Corp cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$422.49K-$147.67K$961.06K-$1.24M-$737.91K-$824.07K$219.20K-$1.60M-$672.28K-$37.15K
Capital expenditures$250$325$977$5.48K$21.46K$9.05K$4.02K$199.19K$1.83K$21.94K
Investing cash flow$416.14K-$13.99K-$5.72K$994.65K-$28.53K-$15.65K$554.40K-$203.16K$63.31K$3.65K
Financing cash flow$13.61K$59.71K$266.54K$34.19K-$1.03K-$860-$142.39K-$55.98K$175.41K$26.93K
Net change in cash-$6.03K-$88.41K$1.13M-$180.10K-$552.25K-$797.53K$221.62K-$1.30M-$476.49K-$79.02K
Stock-based compensationUnavailableUnavailable$794.77KUnavailableUnavailableUnavailable$0UnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

BioNexus Gene Lab Corp derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow-$422.74K-$148.00K$960.08K-$1.24M-$759.37K-$833.12K$215.18K-$1.80M-$674.11K-$59.10K
Gross margin17.0%-3.5%-0.8%14.8%16.3%16.1%12.3%12.4%14.6%15.3%
Operating margin-370.8%-2366.2%-213.5%-27.6%-27.0%-28.9%-16.5%-50.9%13.1%-3.3%
FCF margin-555.1%-647.9%198.5%-48.9%-33.6%-39.0%8.5%-68.5%-34.1%-2.5%
SBC / revenueUnavailableUnavailable164.3%UnavailableUnavailableUnavailable0.0%UnavailableUnavailableUnavailable
Current ratio6.08x6.52x10.46x8.30x3.63x4.19x3.81x4.98x5.60x4.61x
Revenue YoY growth-96.6%-98.9%-80.8%-3.3%14.5%-10.3%11.0%3.0%-23.1%0.2%
Net margin-376.1%Unavailable-214.2%-27.9%-27.3%Unavailable-13.8%-51.1%10.1%-4.4%
R&D / revenue18.0%63.4%2.3%0.6%0.6%0.6%0.7%0.4%0.4%0.5%
CapEx / revenue0.3%1.4%0.2%0.2%0.9%0.4%0.2%7.6%0.1%0.9%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable21.8%Unavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BGLC in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-04-14View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-18View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

cash flow reconciliationreview2022-12-31

Operating, investing and financing flows differ from the reported change in cash by 1323300, beyond tolerance 1000000.